RaDaR® ST
MRD Detection & Recurrence Monitoring (Pan-Cancer)
Key Facts
Indication
MRD Detection & Recurrence Monitoring (Pan-Cancer)
Phase
Commercial
Status
Active
Company
About NeoGenomics
NeoGenomics is a mission-driven company focused on transforming cancer care through advanced diagnostic testing and data solutions. Its core strategy leverages a comprehensive, multi-modal testing platform and one of the largest proprietary oncology genomic databases to serve healthcare providers, biopharma partners, and patients. With annual volumes exceeding 1.7 million tests and a growing emphasis on MRD detection and data services, the company is positioned at the intersection of diagnostics and real-world evidence in the expanding precision medicine market.
View full company profile